Ovarian Cancer

ASCO 2026 highlights show dostarlimab may deliver curative potential in dMMR endometrial cancer, while novel ADCs and fasting reshape ovarian care.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Relacorilant plus nab-paclitaxel displayed OS benefit irrespective of prior taxane exposure or taxane-free interval in platinum-resistant ovarian cancer.

Chiauranib plus weekly paclitaxel cut the risk of progression or death by 57% vs placebo plus paclitaxel in platinum-resistant or refractory ovarian cancer.

Nicholas Zorko, MD, PhD, discusses B7-H3 targeting in lung, GU, and gynecologic malignancies.

The FDA has published new sets of product-specific guidelines for investigating generic cancer treatments to guide proper evaluation of bioequivalence.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Poll results reflect some of the most anticipated presentations and fields of interest in gynecologic oncology at the 2026 ASCO Annual Meeting.

Discover which gynecologic cancer abstracts experts believe may affect evolving treatment paradigms and patient care discussions at ASCO 2026.

AVB-001 was tolerable and activated CD8+ and CD4+ T cells without regulatory T-cell expansion in platinum-resistant high-grade serous ovarian carcinoma.

The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

QLS5132 led to a 50% ORR and manageable safety in PROC, supporting CLDN6 as a promising ADC target in early-phase clinical development.

Early evidence suggests a dual bispecific strategy may be able to move the needle forward for patients with platinum-resistant ovarian cancer or endometrial cancer.

Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.

Mirvetuximab soravtansine plus carboplatin showed antitumor activity and a manageable safety profile in patients with recurrent platinum-sensitive ovarian cancer.

Sofetabart mipitecan elicited strong antitumor activity in recurrent platinum-resistant high-grade serous ovarian cancer.

The novel ADC DB-1311/BNT324 was effective in cervical cancer and PROC, regardless of prior treatment or histology

Single-agent rezatapopt showed efficacy and safety irrespective of patients' platinum status, prior bevacizumab or PARP inhibitor exposure, or FRα expression.

Patients who received first-line niraparib as maintenance therapy had high resolution rates and low number of discontinuations due to hematologic PSEOIs.

With 1 year of additional follow-up, avutometinib plus defactinib showed durable efficacy with no new safety concerns in LGSOC.

Results from NRG-GY019 establish chemotherapy followed by letrozole as the definitive SOC for newly diagnosed stage II-IV low-grade serous ovarian carcinoma

Relacorilant plus nab-paclitaxel cuts death risk by 35% and extends survival to 16 months in platinum-resistant ovarian cancer, per final ROSELLA trial data.

CTIM-76 received fast track designation from the FDA for pretreated platinum-resistant ovarian cancer.

Pembrolizumab plus paclitaxel, with or without bevacizumab, is approved in the EU for pretreated platinum-resistant ovarian cancer with PD-L1 expression.